Transplant-Eligible NDMM: Selecting Induction Therapy Based on Risk Status
In the setting of transplant-eligible newly diagnosed multiple myeloma, expert panelists consider how risk status may affect the selection of induction therapy.
Patient Profile 3: A 58-Year-Old with IgG Kappa Multiple Myeloma
Experts present the case of a 58-year-old patient with IgG kappa multiple myeloma and offer their initial impressions.
Key Updates from the GRIFFIN Trial in Multiple Myeloma
Experts on multiple myeloma discuss recent updates from the GRIFFIN trial on patients with transplant-eligible multiple myeloma.
Patient Profile 1: A 45-Year-Old with Transplant-Eligible Multiple Myeloma
A panel of clinical experts presents the case of a patient with high-risk multiple myeloma (MM) who underwent transplant.
Quadruplet Induction Therapy in Patients With Transplant-Eligible NDMM
Shared insight on the advent of quadruplet therapy regimens in the induction setting of transplant-eligible newly diagnosed multiple myeloma.
Treatment Duration and Maintenance Therapy in NDMM
Clinical insights on treatment duration and the decision to place patients with newly diagnosed MM on maintenance therapy.
2-Minute Drill: Trials Needing Follow-Up From the 2023 ASCO Annual Meeting
Thought leaders from various institutions offered their take on the trial the trial they think may need the most follow-up as a next step following the 2023 ASCO Annual Meeting.
Updates on Bispecific T-Cell Engager (BiTE) Antibodies in Relapsed Multiple Myeloma
Abdullah Khan, MBBS, explains the current data on bispecific T-cell engaging antibodies for the treatment of relapsed multiple myeloma.
Available Treatment Options for Patients with Relapsed Multiple Myeloma
Ashley Rosko, MD, presents the case of a 72-year-old woman with relapsed multiple myeloma for discussion.
2-Minute Drill: FDA Action-Worthy Trials From the 2023 ASCO Annual Meeting
Thought leaders from various institutions offered their take on the trial they think may lead to the next FDA approval following data that were presented at the 2023 ASCO Annual Meeting.
Tailoring Treatment Approaches for Patients with MDS
An overview of the various treatment options available for patients with MDS, with an emphasis on the importance of tailoring treatment choices based on risk profiles.
MDS Diagnosis and Risk Stratification
James K McCloskey, MD, Jamie L Koprivnikar, MD, and Christina Cho, MD discuss the diagnosis of myelodysplastic syndrome (MDS) and the importance of risk stratification in guiding treatment decisions.
Treatment Options for Patients with Disease Progression on BCMA-Targeting Bispecifics
The panel discusses how they would approach the treatment of a patient with relapsed/refractory MM who progresses on BCMA-targeting bispecifics.
Step-up Dosing and Monitoring in Patients with MM on Bispecifics: Health System Perspectives
The panel discusses the approach to step-up and treatment dosing for bispecifics in their respective health care systems.
Incorporating Teclistamab in R/R MM: Insights from Clinical Practices Across the US
Expert hematologist-oncologists discuss how they incorporate teclistamab in their clinical practice as well as variations in access to bispecifics and CAR T-cell therapy.
Managing Hematological Toxicities Associated with Bispecifics in MM
Experts on multiple myeloma provide insights on the management of hematological toxicities associated with bispecific antibodies.
Patient Case 2: A 39-Year-Old with Progressive Disease After Initial Response to Teclistamab
Melissa Alsina, MD, presents the case of a 39-year-old patient with multiple myeloma who has disease progression after initially responding to teclistamab.
Treatment Considerations With Bispecifics in Multiple Myeloma
Panelists provide a broad-view perspective on established treatment pathways with bispecifics in multiple myeloma and the most prevalent challenges tied to this class of therapy.
Multiple Myeloma: Overview of an Evolving Treatment Landscape
Moderator Cesar Rodriguez, MD, spearheads a discussion on the current state of the multiple myeloma treatment paradigm with a focus on bispecifics in the multiply relapsed setting.
2-Minute Drill: Most Practice-Changing Trial From the 2023 ASCO Annual Meeting
Thought leaders from various institutions offered their take on the most practice-changing trial that came out of the 2023 ASCO Annual Meeting.
.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "Treatment Options for Patients with Disease Progression on BCMA-Targeting Bispecifics")
